Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avantor, Inc.AVTR · Entity 3546 | EVP, Bioscience & Medtech | May 01, 2026 | May 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avantor, Inc.
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,566 |
Reported balance
After 2026-05-01 transaction · row 1
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 146,566 · Balance 146,566 F1: Reflects a grant of restricted stock units that vest in three equal annual installments beginning on May 1, 2027. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.76 · Expires 2036-05-01 | Direct | 246,002 |
Reported balance
After 2026-05-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-01 · Grant · Acquired 246,002 · Balance 246,002 F2: Reflects a grant of stock options that vest in three equal annual installments beginning on May 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted stock units that vest in three equal annual installments beginning on May 1, 2027.
F2: Reflects a grant of stock options that vest in three equal annual installments beginning on May 1, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2026 Filed May 5, 2026 23:40 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantStock Options (Right to Buy) · Derivative | 246,002 | $0.00 Strike: $8.76 | $0.00 |
DisclosureSEC source: 0001628280-26-030825 · wk-form4_1778024423.xml · derivative · entry 2 Brellier Ludovic · CIK 0002132959 · EVP, Bioscience & Medtech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 246,002 Underlying: Common Stock · 246,002 shares Expires 2036-05-01 F2 · derivative.exercise_date: Reflects a grant of stock options that vest in three equal annual installments beginning on May 1, 2027. Read SEC document |
| May 01, 2026 Filed May 5, 2026 23:40 UTC | Avantor, Inc. AVTR · Entity 3546 | GrantCommon Stock | 146,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-030825 · wk-form4_1778024423.xml · nonDerivative · entry 1 Brellier Ludovic · CIK 0002132959 · EVP, Bioscience & Medtech 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,566 F1 · kind: Reflects a grant of restricted stock units that vest in three equal annual installments beginning on May 1, 2027. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.